Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

474.85 +6.44 (+1.37%)
Streaming Delayed Price Updated: 10:07 AM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
News headline image
5 Top Stocks to Buy in October ↗
These five stocks are underperforming the S&P 500 in 2025, but have what it takes to reward investors over the long term. 
Via The Motley Fool
Topics Stocks
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
News headline image
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Assessing Vertex Pharmaceuticals: Insights From 15 Financial Analysts ↗
Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. 
Via Benzinga
News headline image
Vertex Announces Key Advancements Across Kidney Portfolio
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
This Chewy Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
My 3 Favorite Stocks to Buy Right Now ↗
Uncertainty is in the air. But these stocks inspire confidence. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Top GARP Stock ↗
Vertex Pharmaceuticals (VRTX) is a top GARP stock, offering strong revenue growth, high profitability, and a debt-free balance sheet at a reasonable valuation. 
Via Chartmill
News headline image
Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Unpacking Q2 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex... 
Via StockStory
Topics Artificial Intelligence
News headline image
Healthcare Stocks Are at an Historic Low and a Turnaround Is on the Horizon ↗
There is a "for sale" sign on the sector, and these two stocks look particularly attractive at their current levels. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
News headline image
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue. 
Via Benzinga
News headline image
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy
From Vertex Pharmaceuticals
Via Business Wire
News headline image
2 Growth Stocks to Buy and Hold Forever ↗
Look beyond the recent headwinds these two have faced. 
Via The Motley Fool
Topics World Trade
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Screens as a Top Undervalued Stock with Strong Fundamentals ↗
Vertex Pharmaceuticals (VRTX) is a strong value stock with high profitability, zero debt, and solid growth, trading at an attractive valuation within the biotech sector. 
Via Chartmill
News headline image
Why This Biotech Company Could Be a Growth Stock Powerhouse ↗
The stock has soared in the triple-digits over the past decade. 
Via The Motley Fool
News headline image
1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals ↗
Here's why you can't find a Wall Street analyst who will tell you to sell this stock. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Absurdly Cheap Stocks to Buy for the Long Haul ↗
They trade at some incredibly low earnings multiples. 
Via The Motley Fool
News headline image
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Fundamentals and Technical Breakout Potential ↗
Vertex Pharmaceuticals (VRTX) is a top growth stock with strong fundamentals, high profitability, and a technical setup hinting at a potential breakout for investors. 
Via Chartmill
News headline image
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190% ↗
These companies are reaching key milestones. 
Via The Motley Fool
News headline image
1 Safe-and-Steady Stock to Research Further and 2 We Turn Down
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
Why This Biotech Company Could Be a Growth Stock Powerhouse ↗
Recent developments aren't as devastating to the company's prospects as some might think. 
Via The Motley Fool
News headline image
Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Top GARP Stock with Strong Growth and Reasonable Valuation ↗
Vertex Pharmaceuticals (VRTX) exemplifies the GARP strategy with strong growth, a reasonable valuation, high profitability, and a robust debt-free balance sheet. 
Via Chartmill
News headline image
Tuesday's session: top gainers and losers in the S&P500 index ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
News headline image
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
3 No-Brainer Stocks to Buy Right Now ↗
Investing in these pharmaceutical stocks is an easy decision. 
Via The Motley Fool
Topics World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.